act adoptive cell therapy Search Results


adoptive t-cell therapy (act)  (Nature Biotechnology)
90
Nature Biotechnology adoptive t-cell therapy (act)
Adoptive T Cell Therapy (Act), supplied by Nature Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adoptive t-cell therapy (act)/product/Nature Biotechnology
Average 90 stars, based on 1 article reviews
adoptive t-cell therapy (act) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
act adoptive cell therapy  (Human Protein Atlas)
90
Human Protein Atlas act adoptive cell therapy
Act Adoptive Cell Therapy, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/act adoptive cell therapy/product/Human Protein Atlas
Average 90 stars, based on 1 article reviews
act adoptive cell therapy - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
adoptive t cell therapy act  (ACTGene Inc)
90
ACTGene Inc adoptive t cell therapy act
The regulation of PD-1/PD-L1 signaling on immune cells. a . The PD-1/PD-L1 pathway promotes the exhaustion and apoptosis of effector T cells. Tex cells are characterized by increased expression of highly inhibitory receptors, including PD-1, LAG3, and TIGIT, decreased cytokine production such as TNF, IL-2, and IFN-γ, metabolic alterations, and impaired proliferative capacity and survival. b . PD-1/PD-L1 promotes the generation and development of induced Tregs (iTregs) by reducing the phosphorylation of PI3K/Akt/mTOR and S6, while enhancing PTEN, thus enhancing the immune suppression functions of Treg cells and inducing immune tolerance. c . PD-1/PD-L1 can promote the polarization of tumor-associated macrophages (TAM) toward the M2 phenotype, releasing large amounts of fibroblast growth factor, VEGF, TNF-α, and other cytokines to promote angiogenesis and support immune suppression, invasion, and metastasis of cancer cells, accelerating cancer progression. d . PD-1 on NK cells binds to PD-L1 on cancer cells, inhibiting the degranulation and cytotoxic function of NK cells, decreasing their ability to kill tumor cells, and promoting tumor immune escape. The use of PD-1 and PD-L1 <t>inhibitors</t> may reactivate the anti-tumor immune response of the above immune cells. Figure created with BioRender
Adoptive T Cell Therapy Act, supplied by ACTGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adoptive t cell therapy act/product/ACTGene Inc
Average 90 stars, based on 1 article reviews
adoptive t cell therapy act - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
adoptive t cell therapy (act)  (Inserm Transfert)
90
Inserm Transfert adoptive t cell therapy (act)
The regulation of PD-1/PD-L1 signaling on immune cells. a . The PD-1/PD-L1 pathway promotes the exhaustion and apoptosis of effector T cells. Tex cells are characterized by increased expression of highly inhibitory receptors, including PD-1, LAG3, and TIGIT, decreased cytokine production such as TNF, IL-2, and IFN-γ, metabolic alterations, and impaired proliferative capacity and survival. b . PD-1/PD-L1 promotes the generation and development of induced Tregs (iTregs) by reducing the phosphorylation of PI3K/Akt/mTOR and S6, while enhancing PTEN, thus enhancing the immune suppression functions of Treg cells and inducing immune tolerance. c . PD-1/PD-L1 can promote the polarization of tumor-associated macrophages (TAM) toward the M2 phenotype, releasing large amounts of fibroblast growth factor, VEGF, TNF-α, and other cytokines to promote angiogenesis and support immune suppression, invasion, and metastasis of cancer cells, accelerating cancer progression. d . PD-1 on NK cells binds to PD-L1 on cancer cells, inhibiting the degranulation and cytotoxic function of NK cells, decreasing their ability to kill tumor cells, and promoting tumor immune escape. The use of PD-1 and PD-L1 <t>inhibitors</t> may reactivate the anti-tumor immune response of the above immune cells. Figure created with BioRender
Adoptive T Cell Therapy (Act), supplied by Inserm Transfert, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/adoptive t cell therapy (act)/product/Inserm Transfert
Average 90 stars, based on 1 article reviews
adoptive t cell therapy (act) - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


The regulation of PD-1/PD-L1 signaling on immune cells. a . The PD-1/PD-L1 pathway promotes the exhaustion and apoptosis of effector T cells. Tex cells are characterized by increased expression of highly inhibitory receptors, including PD-1, LAG3, and TIGIT, decreased cytokine production such as TNF, IL-2, and IFN-γ, metabolic alterations, and impaired proliferative capacity and survival. b . PD-1/PD-L1 promotes the generation and development of induced Tregs (iTregs) by reducing the phosphorylation of PI3K/Akt/mTOR and S6, while enhancing PTEN, thus enhancing the immune suppression functions of Treg cells and inducing immune tolerance. c . PD-1/PD-L1 can promote the polarization of tumor-associated macrophages (TAM) toward the M2 phenotype, releasing large amounts of fibroblast growth factor, VEGF, TNF-α, and other cytokines to promote angiogenesis and support immune suppression, invasion, and metastasis of cancer cells, accelerating cancer progression. d . PD-1 on NK cells binds to PD-L1 on cancer cells, inhibiting the degranulation and cytotoxic function of NK cells, decreasing their ability to kill tumor cells, and promoting tumor immune escape. The use of PD-1 and PD-L1 inhibitors may reactivate the anti-tumor immune response of the above immune cells. Figure created with BioRender

Journal: Molecular Cancer

Article Title: Regulatory mechanisms of PD-1/PD-L1 in cancers

doi: 10.1186/s12943-024-02023-w

Figure Lengend Snippet: The regulation of PD-1/PD-L1 signaling on immune cells. a . The PD-1/PD-L1 pathway promotes the exhaustion and apoptosis of effector T cells. Tex cells are characterized by increased expression of highly inhibitory receptors, including PD-1, LAG3, and TIGIT, decreased cytokine production such as TNF, IL-2, and IFN-γ, metabolic alterations, and impaired proliferative capacity and survival. b . PD-1/PD-L1 promotes the generation and development of induced Tregs (iTregs) by reducing the phosphorylation of PI3K/Akt/mTOR and S6, while enhancing PTEN, thus enhancing the immune suppression functions of Treg cells and inducing immune tolerance. c . PD-1/PD-L1 can promote the polarization of tumor-associated macrophages (TAM) toward the M2 phenotype, releasing large amounts of fibroblast growth factor, VEGF, TNF-α, and other cytokines to promote angiogenesis and support immune suppression, invasion, and metastasis of cancer cells, accelerating cancer progression. d . PD-1 on NK cells binds to PD-L1 on cancer cells, inhibiting the degranulation and cytotoxic function of NK cells, decreasing their ability to kill tumor cells, and promoting tumor immune escape. The use of PD-1 and PD-L1 inhibitors may reactivate the anti-tumor immune response of the above immune cells. Figure created with BioRender

Article Snippet: Currently, the therapeutic approaches targeting PD-1/PD-L1 include immune checkpoint inhibitors, adoptive T cell therapy (ACT), gene editing therapies, and tumor vaccines, which have been widely applied clinically in advanced cancer patients, particularly in melanoma and lung cancer, achieving remarkable early success and greatly improving the overall survival and progression-free survival of cancer patients [ ].

Techniques: Expressing, Phospho-proteomics